PubRank

Walter J Koch

Author PubWeight™ 248.39‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Seven-transmembrane-spanning receptors and heart function. Nature 2002 5.38
2 A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med 2008 3.98
3 Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation 2002 3.15
4 A novel and efficient model of coronary artery ligation and myocardial infarction in the mouse. Circ Res 2010 3.00
5 Regulation of beta-adrenergic receptor signaling by S-nitrosylation of G-protein-coupled receptor kinase 2. Cell 2007 2.65
6 Adrenal GRK2 upregulation mediates sympathetic overdrive in heart failure. Nat Med 2007 2.48
7 A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 2003 2.32
8 Animal models of heart failure: a scientific statement from the American Heart Association. Circ Res 2012 2.31
9 Elevated myocardial and lymphocyte GRK2 expression and activity in human heart failure. Eur Heart J 2005 2.29
10 G protein-coupled receptor kinase 2 ablation in cardiac myocytes before or after myocardial infarction prevents heart failure. Circ Res 2008 2.22
11 Myocardial adeno-associated virus serotype 6-betaARKct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failure. Circulation 2008 2.17
12 Hyperphosphorylation of the cardiac ryanodine receptor at serine 2808 is not involved in cardiac dysfunction after myocardial infarction. Circ Res 2012 2.16
13 Differential gene expression and genomic patient stratification following left ventricular assist device support. J Am Coll Cardiol 2003 2.08
14 Cardiac-specific ablation of G-protein receptor kinase 2 redefines its roles in heart development and beta-adrenergic signaling. Circ Res 2006 2.08
15 Uncovering G protein-coupled receptor kinase-5 as a histone deacetylase kinase in the nucleus of cardiomyocytes. Proc Natl Acad Sci U S A 2008 1.93
16 C1q/tumor necrosis factor-related protein-3, a newly identified adipokine, is a novel antiapoptotic, proangiogenic, and cardioprotective molecule in the ischemic mouse heart. Circulation 2012 1.90
17 Negative impact of β-arrestin-1 on post-myocardial infarction heart failure via cardiac and adrenal-dependent neurohormonal mechanisms. Hypertension 2013 1.83
18 Gene therapy in heart failure. Circ Res 2008 1.79
19 Cardioprotective effects of thioredoxin in myocardial ischemia and reperfusion: role of S-nitrosation [corrected]. Proc Natl Acad Sci U S A 2004 1.76
20 Pharmacological- and gene therapy-based inhibition of protein kinase Calpha/beta enhances cardiac contractility and attenuates heart failure. Circulation 2006 1.73
21 Biology of intracranial aneurysms: role of inflammation. J Cereb Blood Flow Metab 2012 1.73
22 Stable myocardial-specific AAV6-S100A1 gene therapy results in chronic functional heart failure rescue. Circulation 2007 1.73
23 S100A1 genetically targeted therapy reverses dysfunction of human failing cardiomyocytes. J Am Coll Cardiol 2011 1.68
24 β-Adrenergic regulation of cardiac progenitor cell death versus survival and proliferation. Circ Res 2012 1.66
25 Cardiac S100A1 protein levels determine contractile performance and propensity toward heart failure after myocardial infarction. Circulation 2006 1.64
26 Adrenergic nervous system in heart failure: pathophysiology and therapy. Circ Res 2013 1.62
27 β-arrestin1-biased β1-adrenergic receptor signaling regulates microRNA processing. Circ Res 2013 1.59
28 Cardiac adenoviral S100A1 gene delivery rescues failing myocardium. J Clin Invest 2004 1.58
29 Ischemic neoangiogenesis enhanced by beta2-adrenergic receptor overexpression: a novel role for the endothelial adrenergic system. Circ Res 2005 1.57
30 Targeted inhibition of cardiomyocyte Gi signaling enhances susceptibility to apoptotic cell death in response to ischemic stress. Circulation 2008 1.56
31 Cardiac AAV9-S100A1 gene therapy rescues post-ischemic heart failure in a preclinical large animal model. Sci Transl Med 2011 1.54
32 Level of G protein-coupled receptor kinase-2 determines myocardial ischemia/reperfusion injury via pro- and anti-apoptotic mechanisms. Circ Res 2010 1.52
33 Cardiac G-protein-coupled receptor kinase 2 ablation induces a novel Ca2+ handling phenotype resistant to adverse alterations and remodeling after myocardial infarction. Circulation 2012 1.52
34 Direct evidence of intracrine angiotensin II signaling in neurons. Am J Physiol Cell Physiol 2014 1.51
35 Downregulation of adiponectin induced by tumor necrosis factor α is involved in the aggravation of posttraumatic myocardial ischemia/reperfusion injury. Crit Care Med 2011 1.50
36 Transgenic overexpression of the Ca2+-binding protein S100A1 in the heart leads to increased in vivo myocardial contractile performance. J Biol Chem 2003 1.43
37 Blockade of NOX2 and STIM1 signaling limits lipopolysaccharide-induced vascular inflammation. J Clin Invest 2013 1.40
38 Vascular-targeted overexpression of G protein-coupled receptor kinase-2 in transgenic mice attenuates beta-adrenergic receptor signaling and increases resting blood pressure. Mol Pharmacol 2002 1.38
39 AAV6.βARKct cardiac gene therapy ameliorates cardiac function and normalizes the catecholaminergic axis in a clinically relevant large animal heart failure model. Eur Heart J 2012 1.35
40 Reduction of sympathetic activity via adrenal-targeted GRK2 gene deletion attenuates heart failure progression and improves cardiac function after myocardial infarction. J Biol Chem 2010 1.32
41 Role of Omi/HtrA2 in apoptotic cell death after myocardial ischemia and reperfusion. Circulation 2004 1.32
42 Orai1 and Stim1 regulate normal and hypertrophic growth in cardiomyocytes. J Mol Cell Cardiol 2010 1.32
43 GRK2 as a novel gene therapy target in heart failure. J Mol Cell Cardiol 2010 1.31
44 Calcium influx through Cav1.2 is a proximal signal for pathological cardiomyocyte hypertrophy. J Mol Cell Cardiol 2010 1.31
45 Regulated overexpression of the A1-adenosine receptor in mice results in adverse but reversible changes in cardiac morphology and function. Circulation 2006 1.30
46 Prodeath signaling of G protein-coupled receptor kinase 2 in cardiac myocytes after ischemic stress occurs via extracellular signal-regulated kinase-dependent heat shock protein 90-mediated mitochondrial targeting. Circ Res 2013 1.29
47 Differential myocardial gene expression in the development and rescue of murine heart failure. Physiol Genomics 2003 1.28
48 Lymphocyte levels of GRK2 (betaARK1) mirror changes in the LVAD-supported failing human heart: lower GRK2 associated with improved beta-adrenergic signaling after mechanical unloading. J Card Fail 2006 1.28
49 G protein-coupled receptor internalization signaling is required for cardioprotection in ischemic preconditioning. Circ Res 2004 1.27
50 Targeting myocardial beta-adrenergic receptor signaling and calcium cycling for heart failure gene therapy. J Card Fail 2007 1.27
51 Comparative cardiac gene delivery of adeno-associated virus serotypes 1-9 reveals that AAV6 mediates the most efficient transduction in mouse heart. Clin Transl Sci 2010 1.26
52 Extracellular S100A1 protein inhibits apoptosis in ventricular cardiomyocytes via activation of the extracellular signal-regulated protein kinase 1/2 (ERK1/2). J Biol Chem 2003 1.25
53 G protein-coupled receptor kinase 2 activity impairs cardiac glucose uptake and promotes insulin resistance after myocardial ischemia. Circulation 2011 1.23
54 An adrenal beta-arrestin 1-mediated signaling pathway underlies angiotensin II-induced aldosterone production in vitro and in vivo. Proc Natl Acad Sci U S A 2009 1.22
55 Cardioprotection specific for the G protein Gi2 in chronic adrenergic signaling through beta 2-adrenoceptors. Proc Natl Acad Sci U S A 2003 1.22
56 CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy. Cell Cycle 2012 1.20
57 Cardioprotective effects of erythropoietin in the reperfused ischemic heart: a potential role for cardiac fibroblasts. J Biol Chem 2004 1.20
58 Modulation of adrenal catecholamine secretion by in vivo gene transfer and manipulation of G protein-coupled receptor kinase-2 activity. Mol Ther 2007 1.20
59 Paroxetine is a direct inhibitor of g protein-coupled receptor kinase 2 and increases myocardial contractility. ACS Chem Biol 2012 1.19
60 Targeted beta-adrenergic receptor kinase (betaARK1) inhibition by gene transfer in failing human hearts. Circulation 2004 1.17
61 G protein-coupled receptor kinases in normal and failing myocardium. Front Biosci (Landmark Ed) 2011 1.17
62 Darbepoetin alfa, a long-acting erythropoietin analog, offers novel and delayed cardioprotection for the ischemic heart. Am J Physiol Heart Circ Physiol 2007 1.16
63 Adiponectin: an indispensable molecule in rosiglitazone cardioprotection following myocardial infarction. Circ Res 2009 1.16
64 Ca2+ -dependent interaction of S100A1 with F1-ATPase leads to an increased ATP content in cardiomyocytes. Mol Cell Biol 2007 1.16
65 Exercise promotes angiogenesis and improves beta-adrenergic receptor signalling in the post-ischaemic failing rat heart. Cardiovasc Res 2007 1.15
66 Genetic manipulation of myocardial beta-adrenergic receptor activation and desensitization. J Mol Cell Cardiol 2004 1.15
67 GSK-3alpha directly regulates beta-adrenergic signaling and the response of the heart to hemodynamic stress in mice. J Clin Invest 2010 1.15
68 Level of beta-adrenergic receptor kinase 1 inhibition determines degree of cardiac dysfunction after chronic pressure overload-induced heart failure. Circulation 2005 1.14
69 Adrenal adrenoceptors in heart failure: fine-tuning cardiac stimulation. Trends Mol Med 2007 1.14
70 Beta(2)-adrenergic receptor gene delivery to the endothelium corrects impaired adrenergic vasorelaxation in hypertension. Circulation 2002 1.13
71 Nuclear effects of G-protein receptor kinase 5 on histone deacetylase 5-regulated gene transcription in heart failure. Circ Heart Fail 2011 1.12
72 Targeting Gbetagamma signaling to inhibit prostate tumor formation and growth. J Biol Chem 2003 1.11
73 Cardiomyocyte lipids impair β-adrenergic receptor function via PKC activation. Am J Physiol Endocrinol Metab 2010 1.09
74 Determining the absolute requirement of G protein-coupled receptor kinase 5 for pathological cardiac hypertrophy: short communication. Circ Res 2012 1.09
75 S100A1: a novel inotropic regulator of cardiac performance. Transition from molecular physiology to pathophysiological relevance. Am J Physiol Regul Integr Comp Physiol 2007 1.08
76 Cardiomyocyte-derived adiponectin is biologically active in protecting against myocardial ischemia-reperfusion injury. Am J Physiol Endocrinol Metab 2009 1.08
77 Cigarette smoke and inflammation: role in cerebral aneurysm formation and rupture. Mediators Inflamm 2012 1.08
78 S100A1 decreases calcium spark frequency and alters their spatial characteristics in permeabilized adult ventricular cardiomyocytes. Cell Calcium 2006 1.07
79 Specific beta(2)AR blocker ICI 118,551 actively decreases contraction through a G(i)-coupled form of the beta(2)AR in myocytes from failing human heart. Circulation 2002 1.07
80 Distinct subcellular location of the Ca2+-binding protein S100A1 differentially modulates Ca2+-cycling in ventricular rat cardiomyocytes. J Cell Sci 2005 1.06
81 Adrenal GRK2 lowering is an underlying mechanism for the beneficial sympathetic effects of exercise training in heart failure. Am J Physiol Heart Circ Physiol 2010 1.06
82 Induced overexpression of Na+/Ca2+ exchanger transgene: altered myocyte contractility, [Ca2+]i transients, SR Ca2+ contents, and action potential duration. Am J Physiol Heart Circ Physiol 2009 1.06
83 The beta-adrenergic receptor kinase in heart failure. J Mol Cell Cardiol 2003 1.06
84 Regulation of in vivo cardiac contractility by phospholemman: role of Na+/Ca2+ exchange. Am J Physiol Heart Circ Physiol 2010 1.06
85 TNF-α induces phenotypic modulation in cerebral vascular smooth muscle cells: implications for cerebral aneurysm pathology. J Cereb Blood Flow Metab 2013 1.05
86 Phospholemman and beta-adrenergic stimulation in the heart. Am J Physiol Heart Circ Physiol 2009 1.05
87 Chronic beta-adrenergic receptor stimulation induces cardiac apoptosis and aggravates myocardial ischemia/reperfusion injury by provoking inducible nitric-oxide synthase-mediated nitrative stress. J Pharmacol Exp Ther 2006 1.05
88 Improved myocardial beta-adrenergic responsiveness and signaling with exercise training in hypertension. Circulation 2005 1.04
89 Adrenal beta-arrestin 1 inhibition in vivo attenuates post-myocardial infarction progression to heart failure and adverse remodeling via reduction of circulating aldosterone levels. J Am Coll Cardiol 2011 1.04
90 Alveolar epithelial beta 2-adrenergic receptors: their role in regulation of alveolar active sodium transport. Am J Respir Crit Care Med 2004 1.03
91 Targeting cardiac β-adrenergic signaling via GRK2 inhibition for heart failure therapy. Front Physiol 2013 1.02
92 G protein-coupled receptor kinase 2: a link between myocardial contractile function and cardiac metabolism. Circ Res 2014 1.02
93 Beta-adrenergic receptor-mediated DNA synthesis in cardiac fibroblasts is dependent on transactivation of the epidermal growth factor receptor and subsequent activation of extracellular signal-regulated kinases. J Biol Chem 2002 1.02
94 S100A1 gene therapy preserves in vivo cardiac function after myocardial infarction. Mol Ther 2005 1.01
95 Endothelial S100A1 modulates vascular function via nitric oxide. Circ Res 2008 1.01
96 Constitutive overexpression of phosphomimetic phospholemman S68E mutant results in arrhythmias, early mortality, and heart failure: potential involvement of Na+/Ca2+ exchanger. Am J Physiol Heart Circ Physiol 2011 1.01
97 The small EF-hand Ca2+ binding protein S100A1 increases contractility and Ca2+ cycling in rat cardiac myocytes. Basic Res Cardiol 2002 1.01
98 Distinct roles of E2F proteins in vascular smooth muscle cell proliferation and intimal hyperplasia. Proc Natl Acad Sci U S A 2007 1.01
99 Gi-biased β2AR signaling links GRK2 upregulation to heart failure. Circ Res 2011 1.01
100 Myocardial Ablation of G Protein-Coupled Receptor Kinase 2 (GRK2) Decreases Ischemia/Reperfusion Injury through an Anti-Intrinsic Apoptotic Pathway. PLoS One 2013 1.00
101 Gq-coupled receptor agonists mediate cardiac hypertrophy via the vasculature. Hypertension 2002 1.00
102 Controlled and cardiac-restricted overexpression of the arginine vasopressin V1A receptor causes reversible left ventricular dysfunction through Gαq-mediated cell signaling. Circulation 2011 1.00
103 Simultaneous administration of insulin-like growth factor-1 and darbepoetin alfa protects the rat myocardium against myocardial infarction and enhances angiogenesis. Clin Transl Sci 2008 1.00
104 Phosphorylation of G protein-coupled receptors: GPCR kinases in heart disease. Mol Interv 2003 0.99
105 The role of oxidative stress in cerebral aneurysm formation and rupture. Curr Neurovasc Res 2013 0.99
106 Beta blocker specificity: a building block toward personalized medicine. J Clin Invest 2007 0.99
107 GRK2 inhibition in heart failure: something old, something new. Curr Pharm Des 2012 0.98
108 A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity. Circ Res 2011 0.98
109 Nuclear translocation of cardiac G protein-Coupled Receptor kinase 5 downstream of select Gq-activating hypertrophic ligands is a calmodulin-dependent process. PLoS One 2013 0.97
110 Future g protein-coupled receptor targets for treatment of heart failure. Curr Treat Options Cardiovasc Med 2009 0.97
111 Increasing cardiac contractility after myocardial infarction exacerbates cardiac injury and pump dysfunction. Circ Res 2010 0.97
112 C1q/tumor necrosis factor-related protein-9, a novel adipocyte-derived cytokine, attenuates adverse remodeling in the ischemic mouse heart via protein kinase A activation. Circulation 2013 0.97
113 Inhibition of vascular smooth muscle G protein-coupled receptor kinase 2 enhances alpha1D-adrenergic receptor constriction. Am J Physiol Heart Circ Physiol 2008 0.97
114 Calcineurin inhibition normalizes beta-adrenergic responsiveness in the spontaneously hypertensive rat. Am J Physiol Heart Circ Physiol 2007 0.96
115 Left ventricular dysfunction in murine models of heart failure and in failing human heart is associated with a selective decrease in the expression of caveolin-3. J Card Fail 2010 0.96
116 Heart failure gene therapy: the path to clinical practice. Circ Res 2013 0.95
117 Guidelines for translational research in heart failure. J Cardiovasc Transl Res 2015 0.95
118 Inhibition of CTRP9, a novel and cardiac-abundantly expressed cell survival molecule, by TNFα-initiated oxidative signaling contributes to exacerbated cardiac injury in diabetic mice. Basic Res Cardiol 2012 0.95
119 GRK2 blockade with βARKct is essential for cardiac β2-adrenergic receptor signaling towards increased contractility. Cell Commun Signal 2013 0.95
120 betaARKct: a therapeutic approach for improved adrenergic signaling and function in heart disease. J Cardiovasc Transl Res 2010 0.94
121 Convergence of G protein-coupled receptor and S-nitrosylation signaling determines the outcome to cardiac ischemic injury. Sci Signal 2013 0.94
122 Essential role of caveolin-3 in adiponectin signalsome formation and adiponectin cardioprotection. Arterioscler Thromb Vasc Biol 2012 0.94
123 Aldosterone increases cardiac vagal tone via G protein-coupled oestrogen receptor activation. J Physiol 2013 0.94
124 TRPM2 channels protect against cardiac ischemia-reperfusion injury: role of mitochondria. J Biol Chem 2014 0.94
125 Catheter-based intracoronary myocardial adenoviral gene delivery: importance of intraluminal seal and infusion flow rate. Mol Ther 2003 0.94
126 Impaired neoangiogenesis in β₂-adrenoceptor gene-deficient mice: restoration by intravascular human β₂-adrenoceptor gene transfer and role of NFκB and CREB transcription factors. Br J Pharmacol 2011 0.93
127 Sevoflurane preconditioning attenuates myocardial ischemia/reperfusion injury via caveolin-3-dependent cyclooxygenase-2 inhibition. Circulation 2013 0.92
128 Myocardial injury after ischemia-reperfusion in mice deficient in Akt2 is associated with increased cardiac macrophage density. Am J Physiol Heart Circ Physiol 2011 0.92
129 SLC25A23 augments mitochondrial Ca²⁺ uptake, interacts with MCU, and induces oxidative stress-mediated cell death. Mol Biol Cell 2014 0.92
130 Caveolin-1 deficiency exacerbates cardiac dysfunction and reduces survival in mice with myocardial infarction. Am J Physiol Heart Circ Physiol 2011 0.92
131 Adiponectin inhibits oxidative/nitrative stress during myocardial ischemia and reperfusion via PKA signaling. Am J Physiol Endocrinol Metab 2013 0.91
132 S100A1 gene transfer: a strategy to strengthen engineered cardiac grafts. J Gene Med 2004 0.91
133 A1 adenosine receptor upregulation accompanies decreasing myocardial adenosine levels in mice with left ventricular dysfunction. Circulation 2007 0.91
134 Beta1-adrenergic receptors promote focal adhesion signaling downregulation and myocyte apoptosis in acute volume overload. J Mol Cell Cardiol 2012 0.90
135 Male and female mice overexpressing the beta(2)-adrenergic receptor exhibit differences in ischemia/reperfusion injury: role of nitric oxide. Cardiovasc Res 2002 0.90
136 Dynamic changes in lymphocyte GRK2 levels in cardiac transplant patients: a biomarker for left ventricular function. Clin Transl Sci 2010 0.90
137 Exercise training and beta-blocker treatment ameliorate age-dependent impairment of beta-adrenergic receptor signaling and enhance cardiac responsiveness to adrenergic stimulation. Am J Physiol Heart Circ Physiol 2007 0.90
138 Viral-based myocardial gene therapy approaches to alter cardiac function. Annu Rev Physiol 2004 0.90
139 Myocardial gene transfer and overexpression of beta2-adrenergic receptors potentiates the functional recovery of unloaded failing hearts. Circulation 2002 0.90
140 The second member of transient receptor potential-melastatin channel family protects hearts from ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 2013 0.89
141 Predisposition to arrhythmia and autonomic dysfunction in Nhlh1-deficient mice. Mol Cell Biol 2002 0.89
142 BMP-2 and FGF-2 synergistically facilitate adoption of a cardiac phenotype in somatic bone marrow c-kit+/Sca-1+ stem cells. Clin Transl Sci 2008 0.89
143 Vascular endothelial growth factor blockade prevents the beneficial effects of β-blocker therapy on cardiac function, angiogenesis, and remodeling in heart failure. Circ Heart Fail 2013 0.89
144 Overexpression of wild-type Galpha(i)-2 suppresses beta-adrenergic signaling in cardiac myocytes. FASEB J 2003 0.89
145 Acute ischemic cardiac dysfunction is attenuated via gene transfer of a peptide inhibitor of the beta-adrenergic receptor kinase (betaARK1). J Gene Med 2005 0.89
146 Targeting G protein-coupled receptor kinases (GRKs) in Heart Failure. Drug Discov Today Dis Mech 2010 0.88
147 Cigarette smoke modulates vascular smooth muscle phenotype: implications for carotid and cerebrovascular disease. PLoS One 2013 0.88
148 Cardiac-restricted overexpression of the A(2A)-adenosine receptor in FVB mice transiently increases contractile performance and rescues the heart failure phenotype in mice overexpressing the A(1)-adenosine receptor. Clin Transl Sci 2008 0.88
149 Alterations in mitochondrial function in a mouse model of hypertrophic cardiomyopathy. Am J Physiol Heart Circ Physiol 2002 0.88
150 Cardiac hypertrophy and altered beta-adrenergic signaling in transgenic mice that express the amino terminus of beta-ARK1. Am J Physiol Heart Circ Physiol 2003 0.88
151 Differential activation of cultured neonatal cardiomyocytes by plasmalemmal versus intracellular G protein-coupled receptor 55. J Biol Chem 2013 0.87
152 S100A1 deficiency impairs postischemic angiogenesis via compromised proangiogenic endothelial cell function and nitric oxide synthase regulation. Circ Res 2012 0.87
153 Regulation of nuclear factor κB (NF-κB) in the nucleus of cardiomyocytes by G protein-coupled receptor kinase 5 (GRK5). J Biol Chem 2013 0.87
154 Involvement of nuclear factor κB (NF-κB) signaling pathway in regulation of cardiac G protein-coupled receptor kinase 5 (GRK5) expression. J Biol Chem 2012 0.87
155 Substrate specificities of g protein-coupled receptor kinase-2 and -3 at cardiac myocyte receptors provide basis for distinct roles in regulation of myocardial function. Mol Pharmacol 2007 0.87
156 S100A1: a calcium-modulating inotropic prototype for future clinical heart failure therapy. Future Cardiol 2007 0.86
157 Reduction of lymphocyte G protein-coupled receptor kinase-2 (GRK2) after exercise training predicts survival in patients with heart failure. Eur J Prev Cardiol 2013 0.86
158 Intracellular endothelin type B receptor-driven Ca2+ signal elicits nitric oxide production in endothelial cells. J Biol Chem 2012 0.86
159 Different potencies of angiotensin receptor blockers at suppressing adrenal β-Arrestin1-dependent post-myocardial infarction hyperaldosteronism. J Am Coll Cardiol 2014 0.86
160 Transgenic mice targeting the heart unveil G protein-coupled receptor kinases as therapeutic targets. Assay Drug Dev Technol 2003 0.86
161 Molecular restoration of beta-adrenergic receptor signaling improves contractile function of failing hearts. Trends Cardiovasc Med 2004 0.85
162 Molecular scaffolds regulate bidirectional crosstalk between Wnt and classical seven-transmembrane-domain receptor signaling pathways. Sci STKE 2007 0.85
163 Urotensin II promotes vagal-mediated bradycardia by activating cardiac-projecting parasympathetic neurons of nucleus ambiguus. J Neurochem 2014 0.84
164 Selective inhibition of heterotrimeric Gs signaling. Targeting the receptor-G protein interface using a peptide minigene encoding the Galpha(s) carboxyl terminus. J Biol Chem 2002 0.84
165 Sealing the leak, healing the heart. Nat Med 2003 0.84
166 Coordinated regulation of cardiac Na(+)/Ca (2+) exchanger and Na (+)-K (+)-ATPase by phospholemman (FXYD1). Adv Exp Med Biol 2013 0.84
167 Substrate uptake and metabolism are preserved in hypertrophic caveolin-3 knockout hearts. Am J Physiol Heart Circ Physiol 2008 0.84
168 Right ventricular targeted gene transfer of a beta-adrenergic receptor kinase inhibitor improves ventricular performance after pulmonary artery banding. J Thorac Cardiovasc Surg 2004 0.84
169 Induced overexpression of Na(+)/Ca(2+) exchanger does not aggravate myocardial dysfunction induced by transverse aortic constriction. J Card Fail 2013 0.84
170 Cardiovascular gene therapy for myocardial infarction. Expert Opin Biol Ther 2013 0.83
171 Apelin receptor: its responsiveness to stretch mechanisms and its potential for cardiovascular therapy. Expert Rev Cardiovasc Ther 2014 0.83
172 Lymphocyte G-protein-coupled receptor kinase-2 is upregulated in patients with Alzheimer's disease. Neurosci Lett 2007 0.83
173 A novel and efficient model of coronary artery ligation in the mouse. Methods Mol Biol 2013 0.83
174 Ethanol protects from injury due to ischemia and reperfusion by increasing vascularity via vascular endothelial growth factor. Alcohol 2012 0.83
175 Prior exercise improves age-dependent vascular endothelial growth factor downregulation and angiogenesis responses to hind-limb ischemia in old rats. J Gerontol A Biol Sci Med Sci 2007 0.83
176 Activation of hypoxia response in endothelial cells contributes to ischemic cardioprotection. Mol Cell Biol 2013 0.83
177 β1-adrenergic receptor and sphingosine-1-phosphate receptor 1 (S1PR1) reciprocal downregulation influences cardiac hypertrophic response and progression to heart failure: protective role of S1PR1 cardiac gene therapy. Circulation 2013 0.83
178 Nesfatin-1 activates cardiac vagal neurons of nucleus ambiguus and elicits bradycardia in conscious rats. J Neurochem 2013 0.82
179 Expression of a beta-adrenergic receptor kinase inhibitor reverses dysfunction in failing cardiomyocytes. Mol Ther 2002 0.82
180 Vascular rarefaction in peripheral skeletal muscle after experimental heart failure. Am J Physiol Heart Circ Physiol 2003 0.81
181 Gene delivery to aortocoronary saphenous vein grafts in a large animal model of intimal hyperplasia. J Thorac Cardiovasc Surg 2004 0.81
182 MCARD-mediated gene transfer of GRK2 inhibitor in ovine model of acute myocardial infarction. J Cardiovasc Transl Res 2012 0.81
183 A role for GRK2 in myocardial ischemic injury: indicators of a potential future therapy and diagnostic. Future Cardiol 2011 0.81
184 Calcium channel function and regulation in beta 1- and beta 2-adrenoceptor transgenic mice. Naunyn Schmiedebergs Arch Pharmacol 2004 0.81
185 Cardiac-restricted expression of the carboxyl-terminal fragment of GRK3 Uncovers Distinct Functions of GRK3 in regulation of cardiac contractility and growth: GRK3 controls cardiac alpha1-adrenergic receptor responsiveness. J Biol Chem 2007 0.81
186 Gene therapy approaches to cardiovascular disease. Methods Mol Med 2005 0.80
187 Catheter-mediated subselective intracoronary gene delivery to the rabbit heart: introduction of a novel method. J Gene Med 2005 0.80
188 Growth inhibition of human hepatocellular carcinoma cells by overexpression of G-protein-coupled receptor kinase 2. J Cell Physiol 2012 0.80
189 Prothymosin alpha protects cardiomyocytes against ischemia-induced apoptosis via preservation of Akt activation. Apoptosis 2013 0.80
190 Induced overexpression of phospholemman S68E mutant improves cardiac contractility and mortality after ischemia-reperfusion. Am J Physiol Heart Circ Physiol 2014 0.79
191 Enhanced calcium cycling and contractile function in transgenic hearts expressing constitutively active G alpha o* protein. Am J Physiol Heart Circ Physiol 2008 0.79
192 Inhibition of angiotensin II Gq signaling augments beta-adrenergic receptor mediated effects in a renal artery stenosis model of high blood pressure. J Mol Cell Cardiol 2008 0.79
193 Heterotopic transplantation as a model to study functional recovery of unloaded failing hearts. J Thorac Cardiovasc Surg 2002 0.79
194 Chronic β1-adrenergic blockade enhances myocardial β3-adrenergic coupling with nitric oxide-cGMP signaling in a canine model of chronic volume overload: new insight into mechanisms of cardiac benefit with selective β1-blocker therapy. Basic Res Cardiol 2014 0.79
195 A pharmacokinetic analysis of molecular cardiac surgery with recirculation mediated delivery of βARKct gene therapy: developing a quantitative definition of the therapeutic window. J Card Fail 2011 0.78
196 Galphaq and its Aktions. J Mol Cell Cardiol 2006 0.78
197 Dose dependent effects of cardiac beta2 adrenoceptor gene therapy. J Surg Res 2004 0.78
198 GRK2 in the heart: a GPCR kinase and beyond. Antioxid Redox Signal 2014 0.78
199 Hearts lacking caveolin-1 develop hypertrophy with normal cardiac substrate metabolism. Cell Cycle 2008 0.78
200 Reduction of vascular intimal-medial hyperplasia in polytetrafluoroethylene arteriovenous grafts via expression of an inhibitor of G protein signaling. Ann Vasc Surg 2005 0.78
201 Inhibition of betaARK1 restores impaired biochemical beta-adrenergic receptor responsiveness but does not rescue CREB(A133) induced cardiomyopathy. J Mol Cell Cardiol 2002 0.78
202 The yin and yang of increased beta-adrenergic signaling: beta1-adrenergic genetic polymorphism and protection against acute myocardial ischemic injury. Am J Physiol Heart Circ Physiol 2006 0.78
203 Alpha2-adrenergic receptor subtype-specific activation of NF-kappaB in PC12 cells. Neurosci Lett 2006 0.78
204 Gene interventions in the beta-adrenergic system for treating heart failure. Semin Thorac Cardiovasc Surg 2003 0.77
205 Gene therapy for heart disease: molecular targets, vectors and modes of delivery to myocardium. Expert Rev Cardiovasc Ther 2013 0.77
206 In vivo adenoviral-mediated gene transfer of the beta ARKct to study the role of G beta gamma in arterial restenosis. Methods Mol Biol 2004 0.77
207 beta2 adrenoceptor gene therapy ameliorates left ventricular dysfunction following cardiac surgery. Eur J Cardiothorac Surg 2004 0.77
208 Polymorphisms present in G-protein-coupled receptor kinases and their effect on β-blocker treatment. Pharmacogenomics 2011 0.76
209 Catheter-mediated delivery of adenoviral vectors expressing beta-adrenergic receptor kinase C-terminus inhibits intimal hyperplasia and luminal stenosis in rabbit iliac arteries. J Gene Med 2004 0.76
210 Differential regulation of TNF receptor 1 and receptor 2 in adiponectin expression following myocardial ischemia. Int J Cardiol 2013 0.76
211 Lymphotoxin-α is a novel adiponectin expression suppressor following myocardial ischemia/reperfusion. Am J Physiol Endocrinol Metab 2013 0.76
212 Negative regulation of VEGF signaling in human coronary artery endothelial cells by G protein-coupled receptor kinase 5. Clin Transl Sci 2009 0.76
213 Tumor necrosis factor-α and lymphotoxin-α mediate myocardial ischemic injury via TNF receptor 1, but are cardioprotective when activating TNF receptor 2. PLoS One 2013 0.76
214 GRK2 negatively regulates IGF-1R signaling pathway and cyclins' expression in HepG2 cells. J Cell Physiol 2013 0.76
215 Methods to improve cardiac gene therapy expression. Expert Rev Cardiovasc Ther 2014 0.75
216 A Gbetagamma inhibitor reduces intimal hyperplasia in aortocoronary saphenous vein grafts. J Thorac Cardiovasc Surg 2005 0.75
217 Targeting β3-Adrenergic Receptors in the Heart: Selective Agonism and β-Blockade. J Cardiovasc Pharmacol 2017 0.75
218 Is erythropoietin behind maladaptive anemic heart failure? Am J Physiol Heart Circ Physiol 2009 0.75
219 Beta-Adrenergic gene therapy for cardiovascular disease. Curr Control Trials Cardiovasc Med 2000 0.75
220 Translational medicine in genetic familial diseases: from the autopsy room to the molecular bench and vice versa. Hum Pathol 2005 0.75
221 Heart failure gene therapy: closer to reality. Professor Walter Koch speaks to Christine Forder, commissioning editor. Future Cardiol 2009 0.75
222 Gene delivery approaches to heart failure treatment. Expert Opin Biol Ther 2004 0.75
223 Gi/o signaling and its potential role in cardioprotection. Expert Rev Cardiovasc Ther 2008 0.75
224 Cardiac βarrestin2 Improves Contractility and Adverse Remodeling in Heart Failure, But Is Underexpressed in Humans. J Am Coll Cardiol 2017 0.75
225 Modification of in vivo cardiac performance by intracoronary gene transfer of beta-adrenergic receptor signaling components. Methods Mol Biol 2003 0.75
226 Gene therapy for heart failure. Ann Med 2004 0.75
227 Donor heart contractile dysfunction following prolonged ex vivo preservation can be prevented by gene-mediated beta-adrenergic signaling modulation. Eur J Cardiothorac Surg 2002 0.75
228 Cardiac gene delivery using DNA-adenoviral constructs. Methods Mol Med 2005 0.75
229 Recent findings into the potential of gene therapy to reverse heart failure. Expert Opin Biol Ther 2007 0.75
230 Highlights of the 2010 scientific sessions of the Heart Failure Society of America, San Diego, California, September 12-15, 2010. J Card Fail 2011 0.75
231 Walter J. Koch: Two Decades, One Mission. Circ Res 2015 0.75
232 Non-canonical roles of GRKs in cardiovascular signaling. J Cardiovasc Pharmacol 2017 0.75
233 Advancing the research mission in an academic department: the creation of a center for translational medicine. Clin Transl Sci 2010 0.75
234 [Activation of sterol regulatory element binding protein and its involvement in endothelial cell migration]. Zhonghua Bing Li Xue Za Zhi 2009 0.75
235 [Gene therapy and benefits in modulating of system beta-adrenergic in cardiac insufficiency]. Rev Med Suisse Romande 2002 0.75
236 GRK2 Regulates α2-Adrenergic Receptor-Dependent Catecholamine Release in Human Adrenal Chromaffin Cells. J Am Coll Cardiol 2017 0.75